Changes of the myocardium in heart failure with preserved ejection fraction: unravelling the role of epicardial adipose tissue

Changes of the myocardium in heart failure with preserved ejection fraction: unravelling the role of epicardial adipose tissue - COMPEAT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56541

Enrollment

400

Registered

2024-02-14

Start date

2024-02-01

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure reduced functioning of the heart

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients undergoing elective cardiac surgery with cardiopulmonary bypass - Legally competent, willing, and able to sign informed consent

Exclusion criteria

Exclusion criteria: - Hemodynamically stable, no inotropic/vasopressic and/or mechanical support prior to surgery. - Active infection or inflammation, e.g. endocarditis, pericarditis - Chronic use of anti-inflammatory medication, e.g. steroids; - Age

Design outcomes

Primary

Measure	Time frame
The main study parameters are EAT-mediated inflammatory biomarkers and their association with clinical parameters for HFpEF, as well as their interaction with cardiomyocyte/endothelium structure and/or function.	—

Secondary

Measure	Time frame
The secondary study paramaters are: - Differences in inflammatory markers between EAT and subcutaneous adipose tissue (EAT) samples and secretomes - Inflammatory biomarkers in plasma and the different with nflammatory biomarkers in EAT samples	—

Countries

Netherlands

Outcome results